<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES SECURITIES AND</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXCHANGE COMMISSION</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center">October 1, 2013</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOVAGEN INGENIUM INC</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 9pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-decoration: underline; text-align: center">Nevada</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-decoration: underline; text-align: center">333-149617</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-decoration: underline; text-align: center">98-0471927</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or other jurisdiction <BR> of incorporation)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 9pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-decoration: underline; text-align: center">9120 Double Diamond Pkwy Ste 2227, Reno, Nevada</TD>
    <TD STYLE="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-decoration: underline; text-align: center">89521</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Wingdings 2">&pound;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 9pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; font-weight: bold">Item 1.01</TD>
    <TD STYLE="font-weight: bold">Entry into a Material Definitive Agreement</TD></TR>
</TABLE>
<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">This document is not intended to provide any other factual information
about the Registrant. Such information can be found in other public filings the Company makes with the SEC, which are available
without charge at www.sec.gov.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>A.&#9;Line of Credit</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">On September 30, 2013, Novagen Ingenium Inc (the &ldquo;Registrant&rdquo;)
entered into a Line of Credit Agreement with Michael Sparavec (the &ldquo;Sparavec Agreement&rdquo;). There was no material relationship
between the Registrant or its affiliates and Mr. Sparavec prior to execution of the Sparavec Agreement.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">Under the terms of the Sparavec Agreement, Mr. Sparavec has established
a $500,000 revolving line of credit in favor of the Registrant (the &ldquo;Sparavec Credit Line&rdquo;). There is no obligation
on Mr. Sparavec to advance any funds under the Sparavec Credit Line. Upon request by the Registrant, Mr. Sparavec may advance some,
all or none of the funds requested by the Registrant for any reason or no reason entirely at his sole and absolute discretion.
Each advance under the Sparavec Credit Line will be secured by a convertible debenture, will accrue simple interest at the rate
of 5% per annum and will be due and payable three years from the date of advance. The Registrant has the right to prepay any amount
owing under a convertible debenture without penalty or bonus. The holder of each convertible debenture will have the right to convert
some or all of the principal amount of the advance secured by the convertible debenture into shares of the Registrant&rsquo;s common
stock at the rate of one common share for each $0.25 of principal.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">The Registrant has agreed to file with the SEC a registration statement
on Form S-1, registering all shares issuable under each convertible debenture within 60 days of the date of the date of the convertible
debenture.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">The Board of Directors of the Registrant approved the Sparavec Agreement
and the transactions contemplated thereby after determining that the Sparavec Agreement and the transactions contemplated thereby
are fair to and in the best interests of the Registrant.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">The description of the terms and conditions of the Sparavec Agreement
set forth herein does not purport to be complete and is qualified in its entirety by reference to the terms of the Sparavec Agreement,
which is filed as Exhibit 10.1 to this Current Report.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">This document is not intended to provide any other factual information
about the Registrant. Such information can be found in other public filings the Company makes with the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;), which are available without charge at www.sec.gov.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>B.&#9;Line of Credit</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">On September 30, 2013, the Registrant entered into a Line of Credit
Agreement with Allan and Beverley Smerdon (the &ldquo;Smerdon Agreement&rdquo;). There is no material relationship between the
Registrant or its affiliates and Allan or Beverley Smerdon prior to execution of the Smerdon Agreement.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">Under the terms of the Line of Credit Agreement, Allan and Beverley
Smerdon (the &ldquo;Smerdons&rdquo;) have established a $500,000 revolving line of credit in favor of the Registrant (the &ldquo;Smerdon
Line of Credit&rdquo;). There is no obligation on the Smerdons to advance any funds under the Smerdon Line of Credit. Upon request
by the Registrant, the Smerdons may advance some, all or none of the funds requested by the Registrant for any reason or no reason
entirely at their sole and absolute discretion. Each advance under the Line of Credit will be secured by a convertible debenture,
will accrue simple interest at the rate of 5% per annum and will be due and payable three years from the date of advance. The Registrant
retains the right to prepay any amount owing under a convertible debenture without penalty or bonus. The holder of each convertible
debenture will have the right to convert some or all of the principal amount of the advance secured by the convertible debenture
into shares of the Registrant&rsquo;s common stock at the rate of one common share for each $0.25 of principal.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">The Registrant has agreed to file with the SEC a registration statement
on Form S-1, registering all shares issuable under each convertible debenture within 60 days of the date of the date of the convertible
debenture.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">The Board of Directors of the Registrant approved the Smerdon Line
of Credit Agreement and the transactions contemplated thereby after determining that the Smerdon Agreement and the transactions
contemplated thereby are fair to and in the best interests of the Registrant.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">The description of the terms and conditions of the Smerdon Agreement
set forth herein does not purport to be complete and is qualified in its entirety by reference to the terms of the Smerdon Agreement,
which is filed as Exhibit 10.2 to this Current Report.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01&#9;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 9pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-weight: bold">(d)</TD>
    <TD STYLE="width: 93%; font-weight: bold">Exhibits</TD></TR>
</TABLE>
<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 9pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">10.1</TD>
    <TD STYLE="width: 93%">Line of Credit Agreement between Novagen Ingenium Inc and Michael Sparavec, dated September 30, 2013</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.2</TD>
    <TD>Line of Credit Agreement between Novagen Ingenium Inc and Allan and Beverley Smerdon, dated September 30, 2013</TD></TR>
</TABLE>
<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Signatures</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in"><B>NOVAGEN INGENIUM INC</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">/s/ Micheal P. Nugent</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">Micheal P. Nugent</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">President &amp; CEO</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">Date: October 1, 2013</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "novz_8k30sep13.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 16570}]
{"company-data": {"conformed-name": "Novagen Ingenium Inc.", "cik": "0001425173", "assigned-sic": "1000", "irs-number": "980471927", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-53671", "film-number": "131126342"}, "business-address": {"street1": "9120 DOUBLE DIAMOND PKWY", "street2": "SUITE 2227", "city": "RENO", "state": "NV", "zip": "89521", "phone": "647-456-9521"}, "mail-address": {"street1": "9120 DOUBLE DIAMOND PKWY", "street2": "SUITE 2227", "city": "RENO", "state": "NV", "zip": "89521"}, "former-company": [{"former-conformed-name": "NOVAGEN SOLAR INC.", "date-changed": "20090512"}, {"former-conformed-name": "Pickford Minerals, Inc.", "date-changed": "20080125"}]}
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
October 1, 2013
NOVAGEN INGENIUM INC
(Exact name of registrant as specified in its
charter)
Nevada
333-149617
98-0471927
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
9120 Double Diamond Pkwy Ste 2227, Reno, Nevada
89521
(Address of principal executive offices)
(Zip Code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01
Entry into a Material Definitive Agreement
This document is not intended to provide any other factual information
about the Registrant. Such information can be found in other public filings the Company makes with the SEC, which are available
without charge at www.sec.gov.
A.	Line of Credit
On September 30, 2013, Novagen Ingenium Inc (the "Registrant")
entered into a Line of Credit Agreement with Michael Sparavec (the "Sparavec Agreement"). There was no material relationship
between the Registrant or its affiliates and Mr. Sparavec prior to execution of the Sparavec Agreement.
Under the terms of the Sparavec Agreement, Mr. Sparavec has established
a $500,000 revolving line of credit in favor of the Registrant (the "Sparavec Credit Line"). There is no obligation
on Mr. Sparavec to advance any funds under the Sparavec Credit Line. Upon request by the Registrant, Mr. Sparavec may advance some,
all or none of the funds requested by the Registrant for any reason or no reason entirely at his sole and absolute discretion.
Each advance under the Sparavec Credit Line will be secured by a convertible debenture, will accrue simple interest at the rate
of 5% per annum and will be due and payable three years from the date of advance. The Registrant has the right to prepay any amount
owing under a convertible debenture without penalty or bonus. The holder of each convertible debenture will have the right to convert
some or all of the principal amount of the advance secured by the convertible debenture into shares of the Registrant's common
stock at the rate of one common share for each $0.25 of principal.
The Registrant has agreed to file with the SEC a registration statement
on Form S-1, registering all shares issuable under each convertible debenture within 60 days of the date of the date of the convertible
debenture.
The Board of Directors of the Registrant approved the Sparavec Agreement
and the transactions contemplated thereby after determining that the Sparavec Agreement and the transactions contemplated thereby
are fair to and in the best interests of the Registrant.
The description of the terms and conditions of the Sparavec Agreement
set forth herein does not purport to be complete and is qualified in its entirety by reference to the terms of the Sparavec Agreement,
which is filed as Exhibit 10.1 to this Current Report.
This document is not intended to provide any other factual information
about the Registrant. Such information can be found in other public filings the Company makes with the Securities and Exchange
Commission (the "SEC"), which are available without charge at www.sec.gov.
B.	Line of Credit
On September 30, 2013, the Registrant entered into a Line of Credit
Agreement with Allan and Beverley Smerdon (the "Smerdon Agreement"). There is no material relationship between the
Registrant or its affiliates and Allan or Beverley Smerdon prior to execution of the Smerdon Agreement.
Under the terms of the Line of Credit Agreement, Allan and Beverley
Smerdon (the "Smerdons") have established a $500,000 revolving line of credit in favor of the Registrant (the "Smerdon
Line of Credit"). There is no obligation on the Smerdons to advance any funds under the Smerdon Line of Credit. Upon request
by the Registrant, the Smerdons may advance some, all or none of the funds requested by the Registrant for any reason or no reason
entirely at their sole and absolute discretion. Each advance under the Line of Credit will be secured by a convertible debenture,
will accrue simple interest at the rate of 5% per annum and will be due and payable three years from the date of advance. The Registrant
retains the right to prepay any amount owing under a convertible debenture without penalty or bonus. The holder of each convertible
debenture will have the right to convert some or all of the principal amount of the advance secured by the convertible debenture
into shares of the Registrant's common stock at the rate of one common share for each $0.25 of principal.
The Registrant has agreed to file with the SEC a registration statement
on Form S-1, registering all shares issuable under each convertible debenture within 60 days of the date of the date of the convertible
debenture.
The Board of Directors of the Registrant approved the Smerdon Line
of Credit Agreement and the transactions contemplated thereby after determining that the Smerdon Agreement and the transactions
contemplated thereby are fair to and in the best interests of the Registrant.
The description of the terms and conditions of the Smerdon Agreement
set forth herein does not purport to be complete and is qualified in its entirety by reference to the terms of the Smerdon Agreement,
which is filed as Exhibit 10.2 to this Current Report.
Item 9.01	Financial Statements and Exhibits.
(d)
Exhibits
10.1
Line of Credit Agreement between Novagen Ingenium Inc and Michael Sparavec, dated September 30, 2013
10.2
Line of Credit Agreement between Novagen Ingenium Inc and Allan and Beverley Smerdon, dated September 30, 2013
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NOVAGEN INGENIUM INC
/s/ Micheal P. Nugent
Micheal P. Nugent
President & CEO
Date: October 1, 2013